Hypertension:血压控制良好的2型糖尿病患者噻嗪类药物使用与心血管事件

2019-11-04 xing.T MedSci原创

由此可见,严格的血压控制可降低未服用噻嗪类药物患者发生MACE和卒中的风险,但在服用噻嗪类药物的患者中则不然。噻嗪类药物对血压相对较低的2型糖尿病患者可能有害。

关于噻嗪类药物在血压控制良好且相对较低的患者中的疗效和安全性的证据尚缺乏。近日,心血管权威杂志Hypertension上发表了一篇研究文章,这项研究旨在评估噻嗪类药物在血压控制良好的2型糖尿病患者中是否有效和安全,以及严格控制血压降低心血管事件的风险是否取决于噻嗪类药物的使用。

研究人员使用控制糖尿病患者心血管风险的措施(ACCORD)研究的数据进行了一项观察性队列研究。该研究的主要结局是主要的不良心血管事件(MACE),包括心血管死亡、心肌梗塞和卒中的复合终点。研究人员使用Cox比例风险模型计算了主要和次要结局的风险比和95%CI。

研究人员纳入了10011名2型糖尿病患者。总体平均随访期为7.7年,有1776名患者经历了MACE。服用和不服用噻嗪类药物的患者的基线平均收缩压分别为137.2和135.7mmHg。噻嗪类药物的使用与MACE风险增加有关,尤其是卒中(风险比为1.49[95%CI为1.18-1.88])。此外,在接受严格的BP控制的患者中,噻嗪类药物的使用与发生MACE和卒中的风险显著相关,而在接受标准BP控制的患者中,使用噻嗪类药物则无较高的风险。在使用倾向得分匹配的分析中观察到相似的关联。

由此可见,严格的血压控制可降低未服用噻嗪类药物患者发生MACE和卒中的风险,但在服用噻嗪类药物的患者中则不然。噻嗪类药物对血压相对较低的2型糖尿病患者可能有害。

原始出处:

Tetsuro Tsujimoto.et al.Thiazide Use and Cardiovascular Events in Type 2 Diabetic Patients With Well-Controlled Blood Pressure.Hypertension.2019.https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.13886

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-10-11 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-01-13 fangcong
  6. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2039112, encodeId=48042039112c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 02 11:49:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728184, encodeId=23001e2818468, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 11 14:49:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971586, encodeId=af2619e1586c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Apr 01 14:49:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643659, encodeId=40c71643659d6, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Aug 03 07:49:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643236, encodeId=fec31643236bf, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Mon Jan 13 04:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383588, encodeId=10d51383588ec, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446308, encodeId=d0cd144630862, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474843, encodeId=f3f014e484395, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501406, encodeId=1ff01501406a8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Nov 06 13:49:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042798, encodeId=34501042e98c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Nov 05 01:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2019-11-05 misszhang

    谢谢MedSci提供最新的资讯

    0